Omniab, Inc. current report, 01 November 2022

Vollständiges Dokument

OmniAb, Inc. Form 8-K Summary

Reporting date: November 1, 2022; filed November 7, 2022. This filing reports completion of OmniAb’s separation from Ligand Pharmaceuticals and its business combination with Avista Public Acquisition Corp. II (“APAC”). It also provides Form 10 information because APAC was a shell company before the transaction.

Business Context and Transaction

  • APAC domesticated from a Cayman Islands entity into a Delaware corporation on October 31, 2022 and changed its name to OmniAb, Inc.
  • On November 1, 2022, Ligand transferred the OmniAb business to Legacy OmniAb, contributed $1.84 million of capital after specified transaction expenses, and distributed Legacy OmniAb shares to Ligand stockholders.
  • APAC’s merger subsidiary merged with Legacy OmniAb, which became a wholly owned subsidiary of OmniAb.
  • Legacy OmniAb shares were exchanged for approximately 82.6 million shares of OmniAb common stock and 15.0 million potential earnout shares. Legacy OmniAb equity awards were converted into awards covering approximately 14.3 million OmniAb shares, plus approximately 2.2 million potential earnout shares.
  • Earnout shares vest based on OmniAb’s volume-weighted average price reaching $12.50 and $15.00 thresholds during specified 20-of-30-trading-day periods within five years of closing, subject to the transaction terms.
  • OmniAb common stock began trading on Nasdaq under “OABI” on November 2, 2022. Warrants began trading under “OABIW.”

Financial Metrics, Capitalization, and Liquidity

  • The filing does not present current-period revenue, profit, operating cash flow, margins, debt balances, or a complete post-closing balance sheet.
  • Historical audited combined financial statements for Legacy OmniAb for 2019–2021 and unaudited financial statements for the six months ended June 30, 2022 and 2021 are incorporated by reference from the proxy statement.
  • Unaudited pro forma combined financial information for APAC and Legacy OmniAb for the year ended December 31, 2021 and six months ended June 30, 2022 is included as Exhibit 99.1; specific figures are not reproduced in the filing text provided.
  • APAC shareholders redeemed 21,713,864 shares for approximately $224.0 million, or approximately $10.32 per share.
  • Approximately $13.3 million remained in the Trust Account immediately before closing. After transaction expenses, the remaining balance was transferred to an OmniAb bank account.
  • OmniAb raised $15.0 million from the Sponsor in exchange for 1.5 million common shares and 1,666,667 warrants.
  • The Sponsor contributed an additional $86.7 million to backstop redemptions in exchange for 8,672,934 common shares and 1,445,489 warrants.
  • The filing does not identify outstanding debt or provide a post-closing liquidity runway.

Material Changes Versus the Prior Comparable Period

  • OmniAb transitioned from a business operated within Ligand to a standalone publicly traded company.
  • The company’s capital structure changed materially through the merger exchange, Sponsor financing, redemption activity, warrant issuance, earnout provisions, and equity-award conversions.
  • APAC ceased to be a shell company upon completion of the Business Combination.
  • Management, the board, governance arrangements, compensation plans, and employee benefit structures were established for the combined company.
  • The filing does not provide a comparative discussion of revenue, earnings, cash flow, or margins versus a prior comparable reporting period.

Guidance, Outlook, Risks, and Unusual Items

  • No quantitative financial guidance is provided.
  • Management’s forward-looking statements address the expected benefits of the Business Combination, future operating performance, market acceptance of OmniAb’s technology platform, addressable markets, and potential milestones and royalties from partner license agreements.
  • Key risks include difficulty operating as a standalone company, loss of Ligand’s brand and resources, limited funds following redemptions and transaction costs, dependence on partners’ product development and commercialization, intellectual-property risks, competition, regulatory changes, technology changes, and Nasdaq listing compliance.
  • The company may have indemnification obligations to Ligand under the Tax Matters Agreement and faces potential costs or adverse outcomes from litigation related to the Business Combination.
  • OmniAb entered into Tax Matters Agreements, Transition Services Agreements, registration rights arrangements, and other ancillary agreements with Ligand, the Sponsor, and related parties.
  • OmniAb has not paid cash dividends and currently expects to retain earnings, if any, for business operations.
  • Annual base salaries and target bonuses were disclosed as follows: Matthew Foehr, $543,609 and 50%; Charles Berkman, $476,834 and 45%; and Kurt Gustafson, $440,000 and 40%.
  • Change-in-control severance agreements provide covered executives with one times base salary, one times the applicable maximum target bonus, health-benefit continuation, and accelerated equity vesting upon qualifying termination.

Important Facts for Investors to Verify

  1. Review Exhibit 99.1 and the incorporated historical financial statements for actual revenue, losses, cash flows, cash balances, and pro forma capitalization.
  2. Confirm the post-closing share count, dilution from public and private warrants, equity awards, and the 15.0 million potential earnout shares.
  3. Assess liquidity after the $224.0 million redemption, transaction expenses, the approximately $13.3 million remaining Trust Account balance, and Sponsor funding.
  4. Review the Tax Matters Agreement and Transition Services Agreements for continuing payments, obligations, indemnities, and reliance on Ligand.
  5. Evaluate partner concentration, milestone and royalty uncertainty, clinical and regulatory dependencies, and the risk that partners do not commercialize successful products.
  6. Monitor Nasdaq listing compliance and the trading performance of OABI and OABIW following the de-SPAC transaction.
  7. Review the proxy statement’s risk factors and the company’s subsequent periodic filings for standalone operating results and updated liquidity information.